Market Research Logo

United States Metered Dose Inhaler Devices Market Outlook to 2023

United States Metered Dose Inhaler Devices Market Outlook to 2023

Summary

GlobalData’s new report, United States Metered Dose Inhaler Devices Market Outlook to 2023, provides key market data on the United States Metered Dose Inhaler Devices market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) for Metered Dose Inhaler Devices.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

  • Market size and company share data for Metered Dose Inhaler Devices.
  • Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.
  • 2016 company shares and distribution shares data for each of the market segments.
  • Global corporate-level profiles of key companies operating within the United States Metered Dose Inhaler Devices market.
  • Key players covered include GlaxoSmithKline Plc, AstraZeneca Plc and Boehringer Ingelheim GmbH.
Reasons to buy
  • Develop business strategies by identifying the key market segments poised for strong growth in the future.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Metered Dose Inhaler Devices Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Metered Dose Inhaler Devices Market, United States
3.1 Metered Dose Inhaler Devices Market, United States, Revenue ($m), 2009-2016
3.2 Metered Dose Inhaler Devices Market, United States, Revenue ($m), 2016-2023
3.3 Metered Dose Inhaler Devices Market, United States, Volume (Units), 2009-2016
3.4 Metered Dose Inhaler Devices Market, United States, Volume (Units), 2016-2023
3.5 Metered Dose Inhaler Devices Market, United States, Average Price ($), 2009-2023
3.6 Metered Dose Inhaler Devices Market, United States, Distribution Share by Revenue ($m), 2015-2016
3.7 Metered Dose Inhaler Devices Market, United States, Company Share by Revenue ($m), 2016
4 Overview of Key Companies in United States, Metered Dose Inhaler Devices Market
4.1 GlaxoSmithKline Plc
4.1.1 Company Overview
4.2 AstraZeneca Plc
4.2.1 Company Overview
4.3 Boehringer Ingelheim GmbH
4.3.1 Company Overview
4.4 Pfizer Inc
4.4.1 Company Overview
4.5 Merck & Co Inc
4.5.1 Company Overview
4.6 Sunovion Pharmaceuticals Inc
4.6.1 Company Overview
5 Financial Deals Landscape
5.1 Debt Offerings
5.1.1 Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036
5.1.2 Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024
5.2 Venture Financing
5.2.1 Propeller Health Raises USD21.5 Million in Series C Financing
6 Recent Developments
6.1 Corporate Communications
6.1.1 Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors
6.1.2 Apr 06, 2017: Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency
6.1.3 Mar 22, 2017: BioStable Science & Engineering Announces FDA Clearance of the HAART 300 Aortic Annuloplasty Device
6.2 Financial Announcements
6.2.1 May 31, 2017: Lamellar Biomedical Recruits First Patients into Clinical Study Assessing LAMELLEYE for Treatment of Dry Eye Disease
6.2.2 May 02, 2017: Merck Announces First-Quarter 2017 Financial Results
6.2.3 Apr 05, 2017: InVivo Therapeutics Announces New Patient Enrollment into the INSPIRE Study at the Carolinas Medical Center
6.2.4 Mar 29, 2017: Peer-Reviewed Clinical Study Shows ID Genomics’ Bacterial Fingerprinting Technology Can Reduce Prescription Errors and Antibiotic Overuse at the Point-of-Care
6.2.5 Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results
6.2.6 Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results
6.3 Government and Public Interest
6.3.1 Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal
6.4 Other Significant Developments
6.4.1 Feb 21, 2017: PharmaCyte Biotech Discusses Patient Enrollment and TD2s Role in Upcoming Clinical Trial
6.4.2 Jan 25, 2017: Daktari Achieves Milestone in Its Merck HCV Collaboration
6.5 Strategy And Business Planning
6.5.1 Dec 01, 2016: Aptar Pharma Nears Completion Of Elastomer Component Capacity In North America
7 Appendix
7.1 Research Methodology
7.1.1 Coverage
7.1.2 Secondary Research
7.1.3 Primary Research
7.1.4 Company Share Analysis
7.1.5 Distribution Share Analysis
7.1.6 Benchmarking
7.2 GlobalData Consulting
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
Table 2: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
Table 3: Metered Dose Inhaler Devices Market, United States, Volume (Units), Historic, 2009-2016
Table 4: Metered Dose Inhaler Devices Market, United States, Volume (Units), Forecast, 2016-2023
Table 5: Metered Dose Inhaler Devices Market, United States, Average Price ($), Historic, 2009-2016
Table 6: Metered Dose Inhaler Devices Market, United States, Average Price ($), Forecast, 2016-2023
Table 7: Metered Dose Inhaler Devices Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016
Table 8: Metered Dose Inhaler Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2016
Table 9: Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036
Table 10: Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024
Table 11: Propeller Health Raises USD21.5 Million in Series C Financing
1.2 List of Figures
Figure 1: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
Figure 2: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
Figure 3: Metered Dose Inhaler Devices Market, United States, Volume (Units), Historic, 2009-2016
Figure 4: Metered Dose Inhaler Devices Market, United States, Volume (Units), Forecast, 2016-2023
Figure 5: Metered Dose Inhaler Devices Market, United States, Company Share (%) 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report